Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Api Corporation is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are assigned to 2 distinct examiners but are concentrated within 1 distinct art unit. This distribution shows that while the technical focus is narrow, the review process is split between different individuals. For practitioners, this means that the prosecution of one case may provide technical insights for the other, even if the examiners differ.
KELLY-O'NEILL, YOLANDA LYNNETTE is the busiest examiner for the company, with 1 busiest examiner pending action. Since this 1 busiest examiner pending action represents only half of the total 2 pending office actions, the company must manage two separate relationships at the patent office. The presence of 2 distinct examiners indicates that the company is navigating different examination styles within the Biotechnology & Pharmaceuticals sector. This decentralized approach requires a flexible strategy for each application.
The 1 distinct art unit involved suggests that the technical subject matter of the filings is highly specialized within a single group. Because there is no concentration of cases with a single official, there is no opportunity to leverage a single favorable ruling across the entire portfolio. Success for the 2 pending office actions will depend on the ability to address the specific requirements of each of the 2 distinct examiners independently while maintaining a consistent technical narrative within the single art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY-O'NEILL, YOLANDA LYNNETTE | 1 | 31.8% | +23.7% |
| CUTLIFF, YATE KAI RENE | 1 | 79.8% | +24.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705667 | METHOD FOR PRODUCING ACETAMINOPHEN | KELLY-O'NEILL, YOLANDA LYNNETTE | — |
| 18681328 | METHOD FOR PRODUCING SALICYLIC ACID | CUTLIFF, YATE KAI RENE | — |
| Art Unit | Apps |
|---|---|
| 1692 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705667 | METHOD FOR PRODUCING ACETAMINOPHEN | KELLY-O'NEILL, YOLANDA LYNNETTE | 1692 | §103 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18681328 | METHOD FOR PRODUCING SALICYLIC ACID | CUTLIFF, YATE KAI RENE | 1692 | §103 | Non-Final OA | — | Pending | Feb 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialApi Corporation has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Yolanda Lynnette Kelly-O'Neill has the most, with 1 of Api Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
